Livoletide

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameLivoletide
Drug Alias NameUAG-analogue-AlizeUnacylated-analogue-AlizeAZP-531
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGhrelin antagonists
TargetsGhrelin
Therapy Area/IndicationsHyperphagiaDiabetes Mellitus, Type 2Prader-Willi Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlizé Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlizé PharmaMillendo Therapeutics Sas
Active IndicationsN/A
Inactive IndicationsHyperphagiaDiabetes Mellitus, Type 2Prader-Willi Syndrome

Other Information

ATC CodeN/A
Related LinksN/A